Can scientific discovery be scheduled?
Barry Werth's The Billion Dollar Molecule is often remembered as a book about biotechnology, drug discovery, and one of the first biotech startups. But beneath the laboratories, venture capital, and pharmaceutical race lies a much deeper question: what happens when investors try to build a business around something fundamentally unpredictable?
In this episode of The Book Brief Project, we explore the remarkable story of Vertex Pharmaceuticals, Joshua Boger, the search for FK-506, and the birth of modern biotechnology. More importantly, we examine why this book ultimately isn't about a molecule at all—it's about the tension between science, ambition, uncertainty, and the limits of planning.
Rather than summarizing every chapter, this episode follows the central idea that gives the book its lasting significance, connecting its lessons to entrepreneurship, innovation, and scientific research today.
Book
The Billion Dollar Molecule — Barry Werth
About The Book Brief Project
The Book Brief Project explores influential nonfiction through cinematic essays that focus on ideas rather than summaries. Each episode examines why a book matters, the questions it raises, and the enduring insights that continue to shape the world long after publication.
If you enjoy thoughtful explorations of science, history, business, philosophy, and technology, consider subscribing for future episodes.